Maclaurin B P, Cooke W T, Ling N R
Gut. 1972 Aug;13(8):614-20. doi: 10.1136/gut.13.8.614.
Evidence is presented which indicates a possible reduction in recognition capacity for tumour cell antigens (EB(2) Burkitt lymphoma cell line) by lymphocytes from some patients with longstanding but inactive Crohn's disease. Three out of seven patients tested also showed diminished or absent lymphocytotoxicity when their cells were grown in mixed culture with chromium-labelled lymphoma cells and absent response has never been observed in a large series of controls similarly tested. In both test systems impaired reactivity appeared to be partly caused by a factor present in Crohn's disease serum. Increased tumour incidence in Crohn's disease may in part be attributable to defective immune surveillance and the histology of Crohn's disease could reflect an imbalance between the proliferative and the cytotoxic responses of lymphocytes to various antigens in the bowel lumen in this disease.
有证据表明,一些患有长期但非活动期克罗恩病的患者的淋巴细胞对肿瘤细胞抗原(EB(2)伯基特淋巴瘤细胞系)的识别能力可能下降。在与铬标记的淋巴瘤细胞进行混合培养时,7名接受测试的患者中有3名的淋巴细胞毒性也减弱或消失,而在大量类似测试的对照中从未观察到无反应情况。在这两种测试系统中,反应性受损似乎部分是由克罗恩病血清中存在的一种因子引起的。克罗恩病中肿瘤发病率的增加可能部分归因于免疫监视缺陷,并且克罗恩病的组织学可能反映了该疾病中淋巴细胞对肠腔内各种抗原的增殖反应和细胞毒性反应之间的失衡。